When does the Tysabri (natalizumab) patent expire?
The exact date depends on which patent(s) you mean—Tysabri has had multiple patents covering different aspects such as composition of the drug, manufacturing, and related methods. Patent expiry is therefore not a single uniform “end date” across all jurisdictions and all claims.
Publicly available, detailed patent-expiry timelines for branded biologics are often piecewise: some patents expire before others, while others may be extended through regulatory or legal mechanisms. To give a precise expiry date, you typically need the specific patent number(s) and the country (for example, US vs. EU), because expiry and any exclusivity periods can differ by jurisdiction.
Is there any Tysabri exclusivity beyond patent expiry?
For biologic medicines like natalizumab, “market exclusivity” can continue even after one patent expires, because exclusivity may be driven by regulatory designation frameworks and by other still-in-force patents covering related claims. The practical result is that biosimilar entry and generic-like competition may be delayed until both:
- relevant patents have expired (and any patent challenges are resolved), and
- any additional regulatory exclusivity periods have ended.
How do patent disputes affect Tysabri’s availability for biosimilar competition?
Even when patents are near expiry, litigation can extend effective exclusivity. If a biosimilar applicant challenges patents or seeks to clarify invalidity/non-infringement, the start of biosimilar launches can shift based on court outcomes and settlement terms. This is common in biologics where multiple overlapping patents cover different claim sets.
What should you check to find the real “expiry date” for Tysabri?
To pinpoint the controlling date, search for:
- the specific drug name (natalizumab/Tysabri) and patent family in your target country,
- the patent numbers that list natalizumab composition or key manufacturing/process claims,
- which patents are still listed as “in force” and their estimated expiry,
- any regulatory exclusivity periods applicable in that jurisdiction,
- any court cases tied to those patents.
Where are the biosimilar timelines most relevant?
If your goal is “when can a cheaper alternative launch,” you’re usually looking for the intersection of:
- the last blocking patent expiry (by jurisdiction), and
- the clearance of regulatory/market-entry requirements.
That tends to be more informative than a single “first patent expiry” date because multiple patents can block launch sequentially.
If you tell me your country, I can narrow it to dates
Patent expiry and exclusivity are jurisdiction-specific. If you share whether you mean the US, UK, EU, or another country (and whether you care about “patent expiry” or “biosimilar launch”), I can narrow the search-intent to the relevant patent set and exclusivity pathway.
Sources
I don’t have any patent database or Tysabri-specific patent-number/expiry details in the provided information, so I can’t cite authoritative expiry dates without risking inaccuracy.